
Pharmacovigilance Signal Detection Assistant
Detect adverse drug signals, assess causality, and prepare regulatory reports
What You Can Do
Analyze adverse event data to identify emerging safety signals, systematically evaluate causal relationships between drugs and adverse events using established frameworks, and generate regulatory-compliant reports for submission. You'll accelerate signal detection workflows, ensure consistent application of causality assessment scales (Naranjo, WHO-UMC), and standardize your pharmacovigilance documentation for FDA, EMA, and ICH submissions.
Features
Identify statistically significant adverse event patterns and emerging safety trends. Analyzes frequency, severity, temporal clustering, and unexpectedness to highlight potential new signals requiring investigation.
Apply Naranjo Scale, WHO-UMC criteria, and Jones Algorithm to systematically evaluate the likelihood that a drug caused an adverse event. Provides transparent scoring and interpretive guidance for each criterion.
Generate compliant Individual Case Safety Reports (ICSR), MedWatch forms (FDA 1639), and Periodic Safety Update Reports (PSUR) formatted for FDA, EMA, and other regulatory authorities.
Detect temporal clustering, demographic risk factors, and unexpected correlations between patient populations, dosing regimens, and outcome severity across adverse event datasets.
Categorize adverse events by severity, seriousness, and regulatory expectedness. Prioritizes investigation based on public health impact and reporting urgency.
Create structured, chronological narratives of adverse events including dosing timeline, event description, and outcome—supporting regulatory submissions and internal safety reviews.
Ensures all outputs conform to ICH-E2A guideline standards, MedDRA coding, and regulatory terminology. Maintains audit trail requirements for regulatory inspections.
Example Output
Signal Detection Summary:
- Elevated incidence of Stevens-Johnson Syndrome in patients aged 18-35 (observed: 12 cases, expected: 2.3, ROR=5.2, 95% CI: 2.8-9.7)
- Temporal clustering: 8 of 12 cases within 2-6 weeks of treatment initiation
- Demographic risk: 75% female (vs. 52% overall population)
Causality Assessment (Naranjo Scale):
- Temporal relationship: 8 points (appropriate onset pattern)
- Dose-response: 3 points (severity correlates with cumulative dose)
- Dechallenge: 5 points (symptom resolution after discontinuation)
- Alternative causes: -2 points (1 concurrent NSAID, 1 viral infection)
- Total Score: 14/13 = Probable ADR ✓
Regulatory ICSR Report (excerpt):
- Case ID: 2026-45821-PV | Suspected Drug: Dexamethasone 4mg daily
- Adverse Reaction: Stevens-Johnson Syndrome, Severe
- Outcome: Hospitalized, recovering | Causality: Probable (Naranjo=14)
- Status: Serious Expedited Report Ready for FDA Submission
What's Included
- Signal Detection Toolkit: Templates and checklists for systematic signal identification, including disproportionality analysis, temporal trend evaluation, and benchmarking against expected background rates.
- Causality Assessment Frameworks: Complete implementations of Naranjo Scale, WHO-UMC categories, and Jones Algorithm with decision trees, scoring logic, and interpretive guidance.
- Regulatory Report Templates: Pre-formatted ICSR, MedWatch (FDA 1639), and PSUR templates aligned with ICH-E2A and regulatory submission standards.
- Case Narrative Generator: Structured prompts and formatting guidelines for creating chronological, complete event narratives suitable for regulatory filing.
- Risk Stratification Criteria: Classification system for serious vs. non-serious, expected vs. unexpected events, with decision logic for investigation priority and reporting urgency.
Who It's For
- Pharmacovigilance Specialists
- Drug Safety Officers and Medical Professionals
- Regulatory Affairs Professionals
- Clinical Trial Safety Monitors
- Post-Market Surveillance Teams
Best For
- Adverse Event Signal Detection and Verification
- Causality Assessment and Documentation
- Regulatory Submissions (ICSR, MedWatch, PSUR)
- Post-Market Surveillance and Trending Analysis
- Clinical Trial Safety Reporting






